Synthetic biology, patenting, health and global justice

Systems and Synthetic Biology

Volumn 7, Issue 3, 2013, Pages 87-98

  van den Belt, Henk ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Access to knowledge; Co construction; Co evolution; Gene patents; Global justice; Health impact fund

Indexed keywords

EID: 84881556104     PISSN: 18725325     EISSN: 18725333     Source Type: Journal    
DOI: 10.1007/s11693-012-9098-7     Document Type: Article

References (57)

1. Andrews L, Shackelton LA (2008) Influenza genetic sequence patents: where intellectual property clashes with public health needs. Future Virol 3: 235-241.
2. BioBricks Foundation (2012) BioBrick™ public agreement: frequently asked questions. https://biobricks. org/bpa/faq/. Accessed 11 June 2012.
3. Boyle J (2010) Monopolist of the genetic code? http://www. thepublicdomain. org/2010/05/28/monopolist-of-the-genetic-code/. Accessed 10 June 2012.
4. Buchanan A, Cole T, Keohane RO (2009) Justice in the diffusion of innovation. J Polit Philos. doi: 10. 1111/j. 1467-9760. 2009. 00348. x.
5. Burk DL, Lemley MA (2002) Is patent law technology-specific? Berkeley Tech L J 17: 1155-1206.
6. Burk DL, Lemley MA (2003) Policy levers in patent law. Va L Rev 89: 1575.
7. Chan S, Sulston J (2010) Patents in synthetic biology may hinder future research and restrict access to innovation. BMJ 340: 1315-1316.
8. Chandrasekharan S, Kumar S, Valley CM, Rai A (2009) Proprietary science, open science and the role of patent disclosure: the case of zinc finger proteins. Nat Biotechnol 27: 140-144.
9. Cook-Deegan R (2011) Gene patents: the shadow of uncertainty. Science 331: 873-874.
10. DeCamp MW (2007) Global health: a normative analysis of intellectual property rights and global distributive justice. Duke University, Thesis.
11. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185.
12. Drugs for Neglected Diseases Working Group (2001) Fatal imbalance: the crisis in research and development for drugs for neglected diseases. Médecins Sans Frontières, Geneva.
13. Dutfield G (2009) Intellectual property rights and the life science industries: past, present and future, 2nd edn. World Scientific, New Jersey.
14. Endy D (2011) On biotechnology without borders. Global Reset. Seedmagazine, 3 March 2011.
15. EPO (2007) Scenarios for the future. How might IP regimes evolve by 2025? What global legitimacy might such regimes have? European Patent Office, Munich.
16. Fidler DP (2008) Influenza virus samples, international law, and global health diplomacy. Emerg Infect Dis 14: 88-94.
17. Forman L (2007) Trade rules, intellectual property, and the right to health. Ethics Int Aff 21: 337-357.
18. Glass JI (2011) Synthetic biology: a new weapon in our war against infectious diseases. In: Conference on emerging and persistent infectious diseases, Edinburgh, October 23-26, 2011. http://www. scienceforglobalpolicy. org/LinkClick. aspx?fileticket=V0Tiy5JoL0g=&tabid=123. Accessed 10 June 2012.
19. Grootendorst P (2009) Patents, public-private partnerships or prizes: how should we support pharmaceutical innovation? University of Toronto, 22 Sept 2009.
20. Hammond E (2009) Indonesia fights to change WHO rules on flu vaccines. April, Seedling.
21. Harvard iGEM Team (2011) Intellectual property and open source technology. http://2011. igem. org/Team: Harvard/Human_Practices. Accessed 17 Sept 2012.
22. Henkel J, Maurer SM (2009) Parts, property and sharing. Nat Biotechnol 27(12): 1095-1098.
23. Herper M (2006) Architect of life: Drew Endy aims to reinvent the biotechnology industry. Forbes, 10 Feb 2006.
24. Hollis A, Pogge Th (2008) The health impact fund: making new medicines accessible to all. Incentives for Global Health (IGH).
25. Holman CM (2012) Debunking the myth that whole-genome sequencing infringes thousands of gene patents. Nat Biotechnol 30: 240-244.
26. Jasanoff S (2004) Ordering knowledge, ordering society. In: Jasanoff S (ed) States of knowledge: the co-production of science and social order. Routledge, London, pp 13-45.
27. Jensen K, Murray F (2005) Intellectual property landscape of the human genome. Science 310: 239-240.
28. Kapczynski A (2008) The access to knowledge mobilization and the new politics of intellectual property. Yale Law J 117: 804-885.
29. Khalil AS, Collins JJ (2010) Synthetic biology: applications come of age. Nat Rev Genet 11: 367-379.
30. Krikorian G, Kapczynski A (eds) (2010) Access to knowledge in the age of intellectual property. Zone Books, New York.
31. Landes WM, Posner RA (2004) The political economy of intellectual property law. The AEI Press, Washington DC.
32. Love J (2008) Pogge and Hollis on the trade-off between access and incentives. Knowl Ecol Int. http://keionline. org/blogs/2008/11/27/trade-off-innov-access. Accessed 17 Sept 2012.
33. MacKenzie D, Wajcman J (1998) The social shaping of technology. Open University Press, Buckingham.
34. May C, Sell S (2006) Intellectual property rights: a critical history. Lynne Rienner Publishers, Boulder.
35. Nathan C (2007) Aligning pharmaceutical innovation with medical need. Nat Med 13(3): 304-308.
36. Oye KA, Wellhausen R (2009) The intellectual commons and property in synthetic biology. In: Schmidt M et al (eds) Synthetic biology. Springer, Berlin, pp 121-139.
37. Palombi L (2009) Gene cartels. Biotech patents in the age of free trade. Edward Elgar, Cheltenham.
38. Pogge Th (2005) Human rights and global health: a research program. Metaphilosophy 36(1/2): 182-209.
39. Posner RA (2012) Why there are too many patents in America. The Atlantic, 12 July 2012.
40. Rai A, Boyle J (2007) Synthetic biology: caught between property rights, the public domain, and the commons. PLoS Biol 5(3): 389-393.
41. Reichman JH (2009) Rethinking the role of clinical trial data in international intellectual property law: the case for a public goods approach. Marquette Intellect Prop Law Rev 13(1): 1-68.
42. Reuters (2012) Court reaffirms right of myriad genetics to patent genes. NY Times, 16 Aug 2012.
43. Rimmer M (2011) Intellectual property and climate change: inventing clean technologies. Edward Elgar, Cheltenham.
44. Roemer-Mahler A (2012) Business conflict and global politics: the pharmaceutical industry and the global protection of intellectual property rights. Rev Int Polit Econ iFirst: 1-32.
45. Ruder WC, Lu T, Collins JC (2011) Synthetic biology moving into the clinic. Science 333: 1248-1252.
46. Rutz B (2009) Synthetic biology and patents. A European perspective. EMBO Rep 10: S14-S16.
47. Schwarz J, Pollack A (2010) Judge invalidates human gene patent. NY Times, 29 March 2010.
48. Shaver L (2009) The right to science and culture. Wisc Law Rev 2010(1): 121-184.
49. Smolke CD (2009) Building outside the box: iGEM and the BioBricks Foundation. Nat Biotechnol 27(12): 1099-1102.
50. Sonderholm J (2010) Intellectual property rights and the TRIPS agreement. An overview of ethical problems and some proposed solutions. World Bank: Policy Research Working Paper 5228.
51. Sunder M (2012) From goods to a good life: intellectual property and global justice. Yale University Press, New Haven and London.
52. van den Belt H (2009) Philosophy of biotechnology. In: Meijers A (ed) Philosophy of technology and engineering sciences. Elsevier, Amsterdam, pp 1301-1340.
53. van den Belt H, Rip A (1987) The Nelson-Winter-Dosi model and synthetic dye chemistry. In: Bijker WE, Hughes TP, Pinch T (eds) The social construction of technological systems. New directions in the sociology and history of technology. MIT Press, Cambridge, MA, pp 135-158.
54. Venter JC (2007) A DNA-driven world. The 32nd Richard Dimbleby lecture. BBC One. December 4, 2007. www. bbc. co. uk/pressoffice/pressreleases/stories/2007/12_december/05/dimbleby. shtml. Accessed 10 June 2012.
55. WHO (2005) Genetics, genomics and the patenting of DNA: review of potential implications for health in developing countries. World Health Organization, Geneva.
56. WIPO (2007) Patent issues related to influenza viruses and their genes. Working paper.
57. Zhang JY (2011) The 'national' and the 'cosmos': the emergence of synthetic biology in China. EMBO Rep 12(4): 302-306.